Pfizer's Lipitor Patent Invalidated In South Korea
A South Korean court on Thursday upheld an earlier ruling that Pfizer's Lipitor patent was invalid and that the generic made by five South Korean pharmaceutical companies did not breach the patent, Reuters reported.
Korean drug companies producing the generic include Dong-A Pharmaceutical and Boryung Pharmaceutical.
Pfizer plans to appeal the ruling in the Korean Supreme Court.
“We are hopeful that a higher court will reverse...
To view the full article, register now.